Pneumonologie

, Volume 145, Issue 1, pp 305–323 | Cite as

Bilanz der Chemotherapie der Tuberkulose

  • E. Jancik
Article
  • 13 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. American Thoracic Society: Ethambutol in the treatment of tuberculosis. A statement by the Committee on Therapy. Amer. Rev. resp. Dis.98, 320–321 (1968 a).Google Scholar
  2. —— Adrenal corticosteroids and tuberculosis. A statement by the Committee on Therapy. Amer. Rev. resp. Dis.97, 484–485 (1968 b).Google Scholar
  3. —— Therapy of pleural effusion. A statement by the Committee on Therapy. Amer. Rev. resp. Dis.97, 479–483 (1968 c).Google Scholar
  4. —— Abstracts of papers presented at the Annual Meeting of the ATS held in conjunction with the Meetings of the National Tuberculosis and Respiratory Disease Association and the National Respiratory Disease Conference, May 24–26, 1969. Amer. Rev. resp. Dis.99, 969–971 (1969 a).Google Scholar
  5. —— A statement by the Committee on Therapy: Intermittent chemotherapy for tuberculosis. Amer. Rev. resp. Dis.100, 257–259 (1969 b).Google Scholar
  6. Batten, J. C.: Rifampicin in treatment of experimental tuberculosis in mice. Tubercle (Lond.)50, 294–298 (1969).PubMedGoogle Scholar
  7. —— Rifampicin in the treatment of experimental tuberculosis in mice: Sterilization of tubercle bacilli in the tissues. Tubercle (Lond.)51, 95–99 (1970).PubMedGoogle Scholar
  8. Bek, E., Bukalska, Z., Stachlewska, S. Zachara, A.: Criteria of inactivity in pulmonary tuberculosis with correct chemotherapy. Gruźlica36, 897–901 (1968).Google Scholar
  9. Bernard, E.: Traitement des tuberculoses pulmonaires invétérées (hyperchroniques) à bacilles résistants, par la polychimiothérapie antibacillaire. Bull. Un. int. Tuberc.41, 183–185 (1968).Google Scholar
  10. Bethlem, N., Mendes, W.: Blind treatment of tuberculosis with second-line drugs. Hospital (Rio)74, 5 (1968).Google Scholar
  11. Bignall, J. R., Lind, A., et Coll.: Comparaison des régimes d'éthionamide, de pyrazinamide et de cyclosérine dans le traitement de malades atteints de tuberculose pulmonaire et déjà traités antérieurement. Bull. Un. int. Tuberc.42, 7–64 (1969).Google Scholar
  12. Böszörményi, M., Fauszt, I., Károlyi, A., Seri, I., Vámos, K.: Nos premières expériences cliniques sur la rifampicine. Acta tuberc. pneumol. belg.60, 471–477 (1969).PubMedGoogle Scholar
  13. British Medical Research Council: Emergence of bacterial resistance in pulmonary tuberculosis under treatment with isoniazid, streptomycin plus PAS, streptomycin plus PAS and streptomycin plus isoniazid. Lancet1953 aII, 217–223.Google Scholar
  14. —— Laboratory techniques for the determination of sensitivity of bacilli to isoniazid, streptomycin and PAS. Lancet1953 bII, 213–217.Google Scholar
  15. —— Isoniazid in the treatment of pulmonary tuberculosis. Brit. med. J.1953 cI, 521–536.Google Scholar
  16. —— Long-term chemotherapy in the treatment of chronic pulmonary tuberculosis with cavitation. Tubercle (Lond.)43, 201–368 (1962).Google Scholar
  17. British Tuberculosis Association: A trial of corticotrophin and prednisone with chemotherapy in pulmonary tuberculosis. Tubercle (Lond.)42, 391–412 (1961).Google Scholar
  18. —— A comparison of the toxicity of prothionamide and ethionamide. Tubercle (Lond.)49, 125–135 (1968).Google Scholar
  19. Brocard, H., Akoun, G., Depierre, A., Muon, N., Tobé, F. M.: La rifampicine dans le traitement de la tuberculose pulmonaire. A propos de 40 observations. Rev. Tuberc. (Paris)33, 173–176 (1969).Google Scholar
  20. Brouet, G.: Action thérapeutique des nouveaux antibiotiques. Critères d'activité. Seizième Congrès National de la Tuberculose et des Maladies Respiratoires, Bordeaux, 2, 3 et 4 Avril 1970, pp. 263, pp. 163–200. Paris: Masson et Cie 1970.Google Scholar
  21. —— Marche, J., Rist, N., Chevalier, J., Le Meur, G.: Thioamide de l'acide alpha-éthylisonicotinique (1314 TH). Étude clinique. Bull. Un. int. Tuberc.28, 228–240 (1958).Google Scholar
  22. —— Modai, J., Vergez, P.: Essais cliniques de la rifampicine en monothérapie. Rev. Tuberc. (Paris)33, 121–132 (1969).Google Scholar
  23. Canetti, G., Grosset, J.: Teneur des souches sauvages de Mycobacterium tuberculosis en variants résistants à l'isoniazide et en variants à la streptomycine sur milieu de Loewenstein-Jensen. Ann. Inst. Pasteur101, 28–46 (1961).Google Scholar
  24. —— —— Mésure de la sensibilité du bacille tuberculeux aux drogues antibacillaires par la méthode des proportions. Rev. Tuberc. (Paris)27, 217–272 (1963).Google Scholar
  25. —— Grumbach, F., Grosset, J.: Long-term two stage chemotherapy of advanced experimental murine tuberculosis with intermittent regimes during the second stage. Tubercle (Lond.)44, 236–240 (1963).PubMedGoogle Scholar
  26. —— Le Lirzin, M., Porven, G.: Comparaison entre la rifampicine et l'isoniazide. Dilutions inhibitrices minimales du sérum de l'homme aux doses thérapeutiques habituelles. Rev. Tuberc. (Paris)33, 91–94 (1969 a).Google Scholar
  27. —— —— —— Le Lirzin, M. Proven, G. Rist, N., Grumbach, F.: Some Comparative Aspects of Rifampicin and Isoniazid. Tubercle (Lond.)49, 367–376 (1968).PubMedGoogle Scholar
  28. —— Parrot, R., Porven, G., Le Lirzin, M.: Les taux de rifampicine dans le poumon et dans les lésions tuberculeuses de l'homme. Rev. tuberc. pneumol. belg.60, 315–322 (1969 b).Google Scholar
  29. Chaulet, P., Larbaoui, D., Grosset, G., Abderrahim, K.: Intermittent Chemotherapy with Isoniazid and Streptomycin in Algiers. Tubercle (Lond.)48, 128–136 (1967).PubMedGoogle Scholar
  30. Cheung, O. T., Pugsley, H. E.: A Follow-Up Study of 134 Cases of Pulmonary Tuberculosis Treated with Adequate Chemotherapy in 1953–1954. Canad. Med. Ass. J.98, 1182–1183 (1968).PubMedGoogle Scholar
  31. Chicou, F. J., Hétrick, G., Huet, M., Radenac, H., Rist, N.: Comparison of two regimens of oral treatment of pulmonary tuberculosis (ethionamid plus isoniazid, thioacetazone plus isoniazid). Bull. W.H.O.39, 731–769 (1968).PubMedGoogle Scholar
  32. Citron, K. M., May, J. R.: The rifampicin in purulent bronchitis. Tubercle (Lond.)50, 329 (1969).Google Scholar
  33. Constans, P., Morin, Y., Saint-Paul, M., Bonnaud, G., Coury, C., Bariéty, M.: L'association rifampicine-isoniazide. Résultats bactériologiques et radiocliniques du traitement de 56 tuberculoses pulmonaires récentes. Rev. Tuberc. (Paris)33, 147–154 (1969).Google Scholar
  34. —— Saint-Paul, M., Morin, Y., Bonnaud, G., Bariéty, M.: Etude des taux plasmatiques de rifampicine et de leurs variations (440 dosages). Rev. tuberc. pneumol. belg.60, 299–314 (1969).Google Scholar
  35. Corpe, R. F., Blalock, F. A., In: The twenty-seventh Veterans Administration-Armed Forces Pulmonary Disease Research Conference (Report by E. Rothstein). Amer. Rev. resp. Dis.97, 949 (1968).Google Scholar
  36. —— —— A continuing study of patients with „Open-Negative“ status at Battey State Hospital. Amer. Rev. resp. Dis.98, 954–964 (1968).PubMedGoogle Scholar
  37. Crofton, J., In: La signification clinique des mesures de résistance bactérienne. Bull. Un. int. Tuberc.27, 213–279 (1957).Google Scholar
  38. —— Chemotherapy of pulmonary tuberculosis. Brit. med. J.1, 1610 (1959).Google Scholar
  39. —— Treatment of patients with drug-resistance in economically developped countries. Tubercle (Lond.) Suppl.50, 65–68 (1969).Google Scholar
  40. Curry, F. J.: Neighborhood clinics for more effective outpatient treatment of tuberculosis. New Engl. J. Med.279, 1262–1267 (1968).PubMedGoogle Scholar
  41. Daddi, G., Cornia, G., Grassi, C., Perna, G., Scarpazza, G.: Prime osservazioni sull attività della rifampicina per via orale nella tubercolosi polmonare cronica. Atti del XVIII Congresso Italiano di Tisiologia, Milano, 4-5-6-novembre 1966, vol. 2, pp. 531–532.Google Scholar
  42. —— Lucchesi, M., Mancini, P.: La rifampicina nel trattamento intermittente della tubercolosi sperimentale della cavia. Ann. Ist. C. Forlanini29, 35–40 (1969).Google Scholar
  43. —— —— —— Matzeu, M., Rossi, P.: La rifampicina-sensibilità dei micobatteri. Ann. Ist. C. Forlanini29, 17–28 (1969).Google Scholar
  44. —— —— —— Termine, A.: La virulenza dei ceppi di mycobacterium tuberculosis resistenti alla rifampicina. Ann. Ist. C. Forlanini29, 29–33 (1969).Google Scholar
  45. —— —— Rossi, P., Sbampato, M.: La rifampicina nel trattamento della tubercolosi polmonare. Ann. Ist. C. Forlanini29, 3–16 (1969).Google Scholar
  46. Delaude, A., Monnier, J., Albarède, J. L., Bourse, R., Puel, J. Mme: La rifampicine dans le traitement de la tuberculose pulmonaire (Premiers résultats). Rev. Tuberc. (Paris)33, 155–162 (1969).Google Scholar
  47. Destexhe, G. E.: Reprise du traitement par la rifampicine de cas résistants de tuberculose pulmonaire. Acta tuberc. pneumol. belg.60, 501–506 (1969).PubMedGoogle Scholar
  48. Devadatta, S., Menon, N. K., Nazareth, O., Dahakrishna, S., Ramakrishnan, C. V., Somasundaram, P. R., Usha, S. P., Velu, S.: A doubleblind study to determine the maximum tolerated dose of ethionamide, when administered twice-weekly to patients with pulmonary tuberculosis. Tubercle (Lond.)51, 263–269 (1970).PubMedGoogle Scholar
  49. Dickinson, J. M., Ellard, G. A., Mitchison, D. A.: Suitability of isoniazid and ethambutol for intermittent administration in the treatment of tuberculosis. Tubercle (Lond.)49, 351–366 (1968).PubMedGoogle Scholar
  50. —— Mitchison, D. A.: In vitro and animal experiments with rifampicin. Tubercle (Lond.)50, 327 (1969).Google Scholar
  51. —— —— Suitability of rifampicin for intermittent administration in the treatment of tuberculosis. Tubercle (Lond.)51, 82–94 (1970).PubMedGoogle Scholar
  52. Dissmann, E.: La culture sur lames — méthode rapide de mesure de la résistance du bacille tuberculeux aux médicaments. Bull. Un. int. Tuberc.31, 73–87 (1961).Google Scholar
  53. Doust, J. Y., Moatamed, F.: Retreatment program in pulmonary tuberculosis with resistant mycobacteria in South of Iran. Dis. Chest52, 21–23 (1967).PubMedGoogle Scholar
  54. Durante, C., Burzoni, F. J.-M.: Results of a study of the treatment of pulmonary tuberculosis with combined isoniazid and thiacetazone in the province of Marrakech (Morocco). Rev. Tuberc. (Paris)32, 894–859 (1968).Google Scholar
  55. East African/British Medical Research Council Fifth Thiazetazone Investigation: Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East-Africa-Fifth Investigation. Tubercle (Lond.)51, 123–151 (1970).Google Scholar
  56. East African/British Medical Research Council's Investigation: The results from twelve to thirty-six months in patients submitted to two studies of primary chemotherapy for pulmonary tuberculosis in East Africa. Tubercle (Lond.)50, 233–256 (1969).Google Scholar
  57. East African/British Medical Research Council Kenya Tuberculosis Survey Follow-up: Tuberculosis in Kenya: a follow-up of a national sampling survey of drug resistance and other factors. Tubercle (Lond.)51, 1–23 (1970).Google Scholar
  58. East African/British Medical Research Council Pyrazinamide Investigation: A controlled comparison of four regimes of streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis. Tubercle (Lond.)50, 81–114 (1969).Google Scholar
  59. Emerson, P. A., Lacey, R. W., Breach, M. R.: A bacteriological study of thiocarlide monotherapy. Tubercle (Lond.)50, 273–279 (1969).PubMedGoogle Scholar
  60. Espié, J.: Présentation des résultats obtenus lors du traitement de 423 tuberculeux pulmonaires par la rifampicine. Rev. Tuberc. (Paris)33, 307–314 (1969).Google Scholar
  61. Favez, G., Willa, Cl.: Observations préliminaires sur l'emploi de la rifampicine dans le traitement de la tuberculose pulmonaire. Rev. Tuberc. (Paris)33, 199–206 (1969).Google Scholar
  62. Fischer, D.-A., Lester, W., Dye, W. E., Moulding, Th. S.: Re-treatment with isoniazid-resistant tuberculosis. Amer. Rev. resp. Dis.97, 392–398 (1968).PubMedGoogle Scholar
  63. —— —— Schaeffer, W. B.: Infections with atypical mycobacteria. Five year's experience at the National Jewish Hospital. Amer. Rev. resp. Dis.98, 29–34 (1968).PubMedGoogle Scholar
  64. Figueiredo, F. P. de: Treatment of patients with pulmonary tuberculosis classified according to the history of previous chemotherapy and without reference to pretreatment drug sensitivity. Tubercle (Lond.)50, 335–343 (1969).PubMedGoogle Scholar
  65. Fox, W.: The John Barnwell lecture — Changing concepts in the chemotherapy of pulmonary tuberculosis. Amer. Rev. resp. Dis.97, 767–790 (1968).PubMedGoogle Scholar
  66. —— Problems of treatment of drug resistance in the developping countries. Tubercle (Lond.)50, 55–65 (1969).PubMedGoogle Scholar
  67. —— Robinson, D. K., Tall, R., Mitchison, D. A., Kent, P. W., Macfadyen, D. N.: A study of acute intolerance to ethionamide, including a comparison with prothionamide, and the influence of a vitamin B-complex additive in prophylaxis. Tubercle (Lond.)50, 125–143 (1969).PubMedGoogle Scholar
  68. Freerksen, E.: Introductive remarks on rifampicin. Acta tub. pneumol. belg.60, 251–253 (1969).Google Scholar
  69. —— Fortschritte in der Tuberkulose-Behandlung. Isoniazid + Rifampicin + Myambutol als neue “Standardtherapie”. Dtsch. med. Wschr.95, 139–141 (1970).PubMedGoogle Scholar
  70. Freerksen, E., Orlowski, E.-H.: Tuberkulose 1970 — Eine Zwischenbilanz. Deutsche Rentenversicherung, pp. 261–267 (1970).Google Scholar
  71. —— Rosenfeld, M., Orlowski, E.-H.: Isoniazid + Rifampicin + Myambutol, eine neue Standard-kombination für die medikamentöse Behandlung der Tuberkulose. Beitr. Klin. Tuberk.141, 273–296 (1970).Google Scholar
  72. Frenkel, S., Wójcik, B., Jaworski, J.: The fate of tuberculous patients with the “open-negative” syndrome. Gruźlica36, 451–454 (1968).Google Scholar
  73. Gernez-Rieux, C., Tacquet, A., Fournier, P., Macquet, V.: Notre expérience du 1314 Th (Trécator) dans le traitement de la tuberculose pulmonaire. Lille méd.5, 53–60 (1960).Google Scholar
  74. —— —— Devulder, B., Debruyne, J.: Les mycobactérioses humaines. Méthodes actuelles de diagnostic bactériologique. Aspects cliniques, thérapeutiques et épidémiologiques. Seizième Congrès National de la Tuberculose et des Maladies Respiratoires, Bordeaux, 2, 3 et 4 Avril 1970, p. 263, pp. 1–70. Paris: Masson et Cie 1970.Google Scholar
  75. Goldman, K. P.: Treatment of unclassified mycobacterial infection of the lungs. Thorax (Lond.)23, 94–99 (1968).PubMedGoogle Scholar
  76. Govindaraj, M.: Multiple-drug reactions in tuberculosis — an illustrative case. Tubercle (Lond.)49, 416–418 (1968).PubMedGoogle Scholar
  77. Grassi, C. (avec la collaboration d'autres): Traitement des cas de tuberculose chronique avec éthambutol et prothionamide associés à rifampicine ou capréomycine. Rev. Tuberc. (Paris)33, 225–230 (1969).Google Scholar
  78. Grumbach, F.: Comparaison entre la rifampicine et l'isoniazide — Activité expérimentale chez la souris. Rev. Tuberc. (Paris).33, 53–58 (1969 a).Google Scholar
  79. —— Experimental (in vivo) studies of new antituberculous drugs: capreomycin, ethambutol, rifampicin. Tubercle (Lond.) Suppl.50, 12–21 (1969 b).PubMedGoogle Scholar
  80. —— La rifampicine dans les traitements associés, continus et intermittents de la tuberculose expérimentale de la souris. Acta tuberc. pneumol. belg.60, 390–396 (1970).Google Scholar
  81. —— Canetti, G., Le Lirzin, M.: Rifampicin in daily and intermittent treatment of experimental murine tuberculosis, with emphasis on late results. Tubercle (Lond.)50, 280–293 (1969).PubMedGoogle Scholar
  82. —— Rist, N.: Activité antituberculeuse expérimentale de la rifampicine, dérivé de la rifamycine SV. Rev. Tuberc. (Paris)31, 749 (1967).Google Scholar
  83. Gyselen, A., Simon-Pouthier, F.: Clinical results in first treatment and retreatment of advanced pulmonary tuberculosis with rifampicin. Tubercle (Lond.)50, 328–329 (1969).Google Scholar
  84. —— Verbist, L., Cosemans, J., Lacquet, L. M., Prignot, J., Simon-Pouthier, F., Brabandere, R. de, Devriendt, J.: A cooperative study on rifampicin in original treatment of advanced pulmonary tuberculosis. Acta tuberc. pneumol. belg.60, 563–576 (1969).PubMedGoogle Scholar
  85. —— —— —— —— Vandenbergh, E.: Rifampicin and ethambutol in the retreatment of advanced pulmonary tuberculosis. Amer. Rev. resp. Dis.68, 933–943 (1968).Google Scholar
  86. —— —— Simon-Pouthier, F., Prignot, J., Brabandere, R. de: La rifampicine dans le traitement d'attaque de la tuberculose pulmonaires (Résultats préliminaires d'une étude comparative). Rev. Tuberc. (Paris),33, 133–134 (1969).Google Scholar
  87. Havel, A., Adámak, L., Šimonová, S.: Rifampicin in experimental investigations on mice. Antibiotica et Chemotherapia, vol. 16, pp. 406–415. Basel-München-New York: Karger 1970.Google Scholar
  88. —— —— The effect of capreomycin on “atypical” and avian mycobacterial strains in vitro. Antibiotica et Chemotherapia, vol. 16, pp. 17–19. Basel-München-New York: Karger 1970.Google Scholar
  89. Heinivaara, O., Lindeberg, L., Pätiälä, J.: The frequency of postpleuritic tuberculosis. Scand. J. resp. Dis. Suppl.72, 42–44 (1970).Google Scholar
  90. Hertzog, P., Toty, L., Personne, C., Chevassu, J.: Homolateral relapse after upper, segmental or lobar resections for tuberculosis: A clinical follow-up study. Rev. Tuberc. (Paris)31, 5–16 (1967).Google Scholar
  91. Hollins, J. P., Simmons, A. V.: Jaundice associated with rifampicin. Tubercle (Lond.)51, 328–332 (1970).PubMedGoogle Scholar
  92. Horne, N. W.: Drug-resistant tuberculosis: a review of the world situation. Tubercle (Lond.) Suppl.50, 2–12 (1969).PubMedGoogle Scholar
  93. Horwitz, O.: Public health aspects of relapsing tuberculosis. Amer. Rev. resp. Dis.99, 183–193 (1969).PubMedGoogle Scholar
  94. Høyer, I.: Prognosis of pulmonary tuberculosis in diabetes before and after induction of chemotherapy. Scand. J. resp. Dis. Suppl.74 11 (1970).Google Scholar
  95. Hutás, I., Nyiredy, G.: Comparative function studies in cases of exsudative pleurisy treated with and without corticosteroids. Acta tuberc. scand.38 12–17 (1960).PubMedGoogle Scholar
  96. Jančík, E.: The treatment of pulmonary tuberculosis in patients harbouring bacilli resistant to the three major drugs. Symposium held in Paris on September 8, 1960 and presided over by E. Jančik (Czechoslovakia), Members: N. W. Horne (Great Britain), Prof. B. Kreis (France), Prof. M. Lucchesi (Italy), J. W. Raleigh (U.S.A.) and Prof. M. Zierski (Poland). Bull. int. Tuberc.31 4–60 (1961).Google Scholar
  97. -- Ethionamid treatment in Czechoslovakia: A preliminary report. Trans 21st Res. Conf. pulm. Dis. VA-AF (St. Louis) 311–321 (1962).Google Scholar
  98. —— Etude comparative des résultats obtenus par les associations chimiothérapiques majeures chez des malades à bacilles de résistance basse et chez des malades à bacilles de résistance élevée, à la même drogue. Bull. Un. int. Tuberc.33 100–119 (1963).Google Scholar
  99. —— Die Behandlung von Lungentuberkulosekranken mit resistenten Tuberkelbazillen. Z. Tuberk.122 131–140 (1964 a).PubMedGoogle Scholar
  100. —— Effects des agents antibacillaires dits secondaires sur la tuberculose pulmonaire. Progr. Explor. Tuberc., vol. 13, pp. 121–218. Basel-München-New York: Karger 1964b.Google Scholar
  101. —— Meilleurs régimes chimiothérapiques chez les malades déjà traités dont les bacilles sont résistants aux drogues antibacillaires majeures. Bull. Un. int. Tuberc.35 165–170 (1964 c).Google Scholar
  102. —— Die Behandlung von Tuberkulosekranken mit resistenten Tuberkelbazillen. Wien. med. Wschr.116 925–929 (1966).PubMedGoogle Scholar
  103. —— Methods and fight against chronic tuberculosis in Czechoslovakia. Scand. J. resp. Dis. Suppl.65 105–111 (1968).Google Scholar
  104. —— The use of ethambutol in clinical practice. Tubercle (Lond.) Suppl.50 52–54 (1969).Google Scholar
  105. —— Boučková, I., Jančíková, M., Novák, M.: Clinical and laboratory experiences with cycloserine. Scand. J. resp. Dis. Suppl.71 306–313 (1970).Google Scholar
  106. —— Novák, M., Jančiková, M., Toušek, J., Krátký, J., Feitová, S., Zelenka, M.: Quelques aspects concernant de nouvelles associations de drogues dans le traitement de la tuberculose à bacilles résistants. Bull. Un. int. Tuberc.41 188–191 (1969).Google Scholar
  107. Japan: Cooperative Study Unit on Chemotherapy of Tuberculosis of National Sanatoria in Japan (Chairman S. Sunahara): Comparison of single, double, and triple drug regimens in the re-treatment of drug-resistant pulmonary tuberculosis. Seventh Series of Trial, Part B. Kekkaku43 199–207 (1968).Google Scholar
  108. Japan: A Statement by the Tuberculosis Treatment Research Committee. Kekkaku 1970 a.Google Scholar
  109. Japan: Cooperative Study group of the Japanese National Sanatoria on Atypical Mycobacteria: A study on the frequency of “atypical” mycobacteria in Japanese National sanatoria. Tubercle (Lond.)51 270–279 (1970).Google Scholar
  110. Johanson, W. G., Jr., Nicholson, D. P.: Pulmonary Disease Due to Mycobacterium Kansasii. An analysis of some factors affecting prognosis. Amer. Rev. resp. Dis.99 73–85 (1969).PubMedGoogle Scholar
  111. Kopeć, H.: Early relapses in inactive pulmonary tuberculosis. Gruźlica37 235–242 (1969).Google Scholar
  112. Kraan, J. K., Mulder, R. J.: Ethambutol in the treatment of tuberculosis. Antibiotica et chemotherapia, vol. 1c, pp. 278–280. Basel-München-New York: Karger 1970.Google Scholar
  113. —— —— van Dijk, B.: Controlled study on rifampicin in first treatment of fresh cases of pulmonary tuberculosis. Acta tuberc. pneumol. belg.60 557–562 (1969).PubMedGoogle Scholar
  114. Kreis, B.: Résistance et survivance du bacille tuberculeux aux médications antibacillaires, pp. 734 (siehe S. 672). Paris: Masson et Cie 1966.Google Scholar
  115. —— Conditions d'un traitement ambulatoire correct. Seizième Congrès National de la Tuberculose et des Maladies Respiratoires, Bordeaux 1970, pp. 263, pp. 201–263. Paris: Masson et Cie 1970.Google Scholar
  116. Kropp, R., Jungbluth, H., Radenbach, K. L.: Influence of Capreomycin on renal function (preliminary results). Antibiotica et Chemotherapia, vol. 16, pp. 59–68. Basel-München-New York: Karger 1970.Google Scholar
  117. Kubín, M., Matušková, E.: Serological typing of mycobacteria for tracing possible sources of avian mycobacterial infection in man. Bull. W. H. O.39 657–662 (1968).PubMedGoogle Scholar
  118. Lal, S.: Patient's preference of drugs in the treatment of tuberculosis. Tubercle (Lond.)50 269–272 (1969).Google Scholar
  119. Lamy, P., Anthoine, D., Vaillant, G., Monneau, J. P., Georges, J. C., Caubel, F., Lambert, H.: Étude préliminaire concernant l'action de la rifampicine dans le traitement des tuberculoses pulmonaires chroniques et des rechutes. Intérêt de l'association rifampicine-éthambutol (à propos de 28 observations). Rev. Tuberc. (Paris)33 bis, 209–222 (1969).Google Scholar
  120. Lattimer, J. K.: Our presents aspects of Genitourinary tuberculosis. At the 29 VA-AF Conf., Cincinnati, Jan. 1970. Amer. Rev. resp. Dis.101 787–788 (1970).Google Scholar
  121. Leading Article: Rifampicin. Tubercle (Lond.)50 318–320 (1969 a).Google Scholar
  122. —— The Twentieth International Tuberculosis Conference. Tubercle (Lond.)50 396–400 (1969 b).Google Scholar
  123. Lees, A. W.: Rifampicin toxicity. Tubercle (Lond.)51 222–223 (1970).Google Scholar
  124. Lévi-Valensi, A., Porot, M., Léonardon, P., Miguères, J., Dalet, R.: Les accidents neuropsychiatriques survenant les tuberculeux traités par la cyclosérine. Presse méd.66 849–851 (1958).Google Scholar
  125. Lim, B. T., Aquinas, M.: Ethambutol and capreomycin in the re-treatment of advanced pulmonary tuberculosis. Amer. Rev. resp. Dis.99 792–793 (1969).PubMedGoogle Scholar
  126. Lucchesi, M., Mancini, P., Zubiani, M.: Ricerche sperimentali sull'attività antimicobatterica della rimfampicina: 3-/4-metil-1-piperazinil-iminometil-rifamicina SV. Ann. Ist. Forlanini27 119–136 (1967 a).PubMedGoogle Scholar
  127. —— Pallotta, G., Rossi, P., Sbampato, M.: L'azione terapeutica della rifampicina, derivato 3-/4-metil-1-piperazinil-iminometil-rifamicina SV, nella tubercolosi polmonare. Ann. Ist. Forlanini27 199–227 (1967 b).PubMedGoogle Scholar
  128. Lukas, W.: Ursachen und Mißerfolge in der stationären Behandlung der offenen Lungentuberkulose und Wege zu ihrer Beseitigung vom Standpunkt des Kostenträgers. Beitr. Klin. Tuberk.140 90–101 (1969).Google Scholar
  129. MacDonald, F. M.: In: The Twenty-seventh Veterans Administration-Armed Forces Pulmonary Disease Conference (report by E. Rothstein). Amer. Rev. resp. Dis.97 947 (1968).Google Scholar
  130. Malik, S. K., Martin, C. J.: Tuberculosis, corticosteroid therapy, and pulmonary function. Amer. Rev. resp. Dis.100 13–18 (1969).PubMedGoogle Scholar
  131. Medical Research Council/Miners Chest Disease Treatment Centre: Chemotherapy of pulmonary tuberculosis with pneumoconiosis. Second report to the Medical Research Council from the joint investigators. Tubercle (Lond.)48 1–10 (1967).Google Scholar
  132. Meissner, G.: Rifampicin in chronic polyresistant cases of pulmonary tuberculosis. Acta tuberc. pneumol. belg.60 482–486 (1969).PubMedGoogle Scholar
  133. —— Rifampicin in newly detected, untreated cases of pulmonary tuberculosis. Acta tuberc. pneumol. belg.60 554–556 (1969).PubMedGoogle Scholar
  134. Meyer, A., Nadjar-Fossé, G.: The association of isoniazid and thiocarlide DAT in the treatment of pulmonary tuberculosis. Comparison with the association of isoniazid and PAS or B-PAS. Rev. Tuberc. (Paris)32 371–380 (1968).Google Scholar
  135. Miller, A. B., Nunn, A. J., Tall, R., Mitchison, D. A.: The therapy of pulmonary tuberculosis in Kenya: a comparison of the results achieved in controlled clinical trials with those achieved by the routine treatment Services. Tubercle (Lond.)51 24–38 (1970).Google Scholar
  136. Mitchell, R. S., Lester, W.: Clinical experience with cycloserine in the treatment of tuberculosis. Scand. J. resp. Dis. Suppl.71 94–108 (1970).Google Scholar
  137. Monaldi, V.: La rifampicina (rifamicina AMP) nelle prime applicazioni terapeutiche. Arch. Tisiol.21 863–866 (1966).PubMedGoogle Scholar
  138. Morrère, P., Stain, J. P., Chauvet, M. C., Luce, J. P., Leprovost, J.: Essais cliniques de la rifadine (rifampicine). Rev. Tuberc. (Paris)33 bis, 177–198 (1969).Google Scholar
  139. Mulder-De Jong, M. T., Mulder, R. J., van Dijk, B.: Enkele waarnemingen betreffende longaandoeningen met atypische mycobacterien. Ned. T. Geneesk.113 2025–2027 (1969).Google Scholar
  140. Mulder, R. J., Mulder-De Jong, M. T.: Sterilization of tuberculous lesions in man. Co-report. Exc. Medica Int. Congr. Series, 1970, No.205, 360–363.Google Scholar
  141. Murdoch, J. McC., Stewart, S. M.: Viomycin with oxytetracycline in the treatment of pulmonary tuberculosis. Brit. J. Tuberc.50 85–92 (1956).Google Scholar
  142. Nasiadko, H.: Stabilization of tuberculosis by ambulatory treatment. Gruźlica36 819–825 (1968).Google Scholar
  143. Nitti, V., Ninni, A., Iodice, F.: La mesure de la sensibilité du bacille tuberculeux à la rifampicine (Problèmes techniques et critères des résistances). Rev. Tuberc. (Paris)33 bis, 25–32 (1969).Google Scholar
  144. Novák, M., Feitová, S., Allegra, L.: Crescita del M. T. su terreno di Loewenstein-Jensen modificato per acidificazione ai fini dell' esecuzione del test di resistenza alla pirazinamide. Riv. sic. Tuberc. Mal. resp.19 429–439 (1965).Google Scholar
  145. —— Krátký, J., Feitová, S.: Assessment of the sensitivity and resistance of M. tuberculosis to pyrazinamide. Stud. pneumol. phtiseol. csl.30 22–28 (1970).Google Scholar
  146. Olejníček, M., Weberová, M., Novák, M., Jančík, E.: A controlled trial of isoniazid and 4–4 diisoamyloxythiosemicarbanilide compared with isoniazid and PAS and isoniazid, streptomycin and PAS. Tubercle (Lond.)46 188–192 (1965).Google Scholar
  147. Onsted, G. D., Sbarbaro, J. A., Rotenberg, L.: Posthospital chemotherapy of the unreliable patient. Amer. Rev. resp. Dis.101 258–264 (1970).PubMedGoogle Scholar
  148. Perret, L.: Pulmonary tuberculosis and diabetes mellitus. Scand. J. resp. Dis. Suppl.72 68–71 (1970).Google Scholar
  149. Pickroth, G., Anschel, R., Kalich, R., Kandt, D.: Rifampicin in the treatment of chronic pulmonary tuberculosis. Investigations on clinical activity and side effects. Acta tuberc. pneumol. belg.60 513–518 (1969).PubMedGoogle Scholar
  150. Pines, A.: Treatment of drug-resistant tuberculosis and preliminary results obtained with rimactane. In: A Symposium on Rimactane. Basle, 1st Nov. 1968, pp. 96–99. Ciba Basel.Google Scholar
  151. Place, V. A., Pyle, M. M., Huerga, J. de la: Ethambutol in tuberculous meningitis. Amer. Rev. resp. Dis.69 783–785 (1969).Google Scholar
  152. Poole, G., Stradling, P.: Intermittent chemotherapy for tuberculosis in an urban community. Brit. med. J.1 82–84 (1969).PubMedGoogle Scholar
  153. Pyle, M. M.: Clinical applications of ethambutol. Tubercle (Lond.) Suppl.50 30–32 (1969).Google Scholar
  154. Radenbach, K. L., Hauck, S., Rossberg, G.: Möglichkeiten und Grenzen der Tuberkulose-Behandlung mit Kanamycin. Beitr. Klin. Tuberk.125 78–96 (1962).Google Scholar
  155. —— Results of clinical studies with capreomycin, ethambutol and rifampicin in the Heckeshorn Hospital, Berlin. Scand. J. resp. Dis. Suppl.69 43–53 (1969 a).Google Scholar
  156. —— Vermeidbare Fehler der antituberkulösen Chemotherapie. Beitr. Klin. Tuberk.140 128–141 (1969 b).Google Scholar
  157. —— Konservative Behandlung der Urogenitaltuberkulose in Klinik und Praxis. Act. Urol.1 151–163 (1970).Google Scholar
  158. Raleigh, J.: In: Rothstein, E., The Twenty Ninth Veterans Administration — Armed Forces Pulmonary Diseases Research Conference. Amer. Rev. resp. Dis.101 783–801 (1970).Google Scholar
  159. Ramakrishnan, C. V., Devadatta, S., Evans, C., Fox, W., Menon, N. K., Nazareth, O., Rahakrishna, S., Sambamoorthy, S., Stott, H., Tripathy, S. P., Velu, S.: A four-year follow-up of patients with quiescent pulmonary tuberculosis at the end of a year of chemotherapy with twice weekly isoniazid plus streptomycin or daily isoniazid plus PAS. Tubercle (Lond.)50 115–124 (1969).Google Scholar
  160. —— Janardhanam, B., Krishnamurty, D. V., Stoot, H., Subbamal, S., Tripathy, S. P.: Toxicity of pyrazinamide, administered one weekly in high dosage. In: Tuberculous Patients. Bull. W.H.O.39 775–779 (1968).Google Scholar
  161. Regli, J.: Erfahrungen mit Rimactan in der stationären Tuberkulosebehandlung. In: A Symposium on Rimactane. Basle, 1st Nov. 1968, pp. 91–95. Ciba, Basel.Google Scholar
  162. Repo, U. K., Hellström, P.-E.: Capreomycin and ethambutol in pulmonary tuberculosis. A preliminary report. Scand. J. resp. Dis. Suppl.72 72–75 (1970).Google Scholar
  163. Riess, W.: The optimum dosage schedule for rimactane. A Symposium on rimactane, Ciba. Basel, 1st Nov. 1968, pp. 36–42.Google Scholar
  164. Riska, N., Rinne, T.: Rifampicin in the treatment of tuberculosis. Scand. J. resp. Dis. Suppl.74 11 (1970).Google Scholar
  165. Rist, N.: Le thioamide de l'acide alpha-éthylisonicotinique (1314 TH). Bull. Un. int. Tuberc.28 220–228 (1958).Google Scholar
  166. -- La résistance du bacille tuberculeux à la rifampicine. Rev. Tuberc. (Paris)33 bis, 33–37 (1969).Google Scholar
  167. Robitzek, E. H., Selikoff, F. J., Ornstein, G. G.: Chemotherapy of human tuberculosis with hydrazine derivates of isonicotinic acid. Quart. Bull. Sea View Hosp.13 27–51 (1952).Google Scholar
  168. Rothstein, E.: The Twenty-ninth Veterans-Administration Pulmonary Disease Research Conference (Cincinnati, Ohio, Jan. 26 to 28, 1970). Amer. Rev. resp. Dis.101 783–801 (1970).Google Scholar
  169. Sbarbaro, J. A., Johnson, S.: Tuberculous chemotherapy for recalcitrant outpatients administered directly twice weekly. Amer. Rev. resp. Dis.97 895–903 (1968).PubMedGoogle Scholar
  170. Schonell, M. E., Crofton, J. W., Stuart, A. E., Wallace, A.: Disseminated infection with mycobacterium avium: Part I — Clinical features, treatment and pathology. Tubercle (Lond.)49 12–30 (1968).Google Scholar
  171. Schütz, I.: A comparison of rifampicin, ethambutol and PAS in short-term monotherapy. (Preliminary results of the third cooperative study of the WATL). Acta tuberc. pneumol. belg.60 437–441 (1969).PubMedGoogle Scholar
  172. —— Bartmann, K., Radenbach, K. L., Siegler, W.: Vergleich der Verträglichkeit von Prothionamid und Ethionamid im Doppelblindversuch. Beitr. Klin. Tuberk.140 296–303 (1969).Google Scholar
  173. —— Radenbach, K. L., Bartmann, K.: The combination of ethambutol, capreomycin and a third drug in chronic pulmonary tuberculosis with bacterial polyresistance. Antibiotica et chemotherapia, vol. 16, pp. 43–58. Basel-München-New York: Karger 1970.Google Scholar
  174. Schwartz, W. S., Tucker, W. S.: Kanamycin in the treatment of pulmonary tuberculosis. Bull. Un. int. Tuberc.30 322–327 (1960).Google Scholar
  175. Sellergren, T. L.: Relapse of tuberculosis in relation to previous treatment. Scand. J. resp. Dis. Suppl.72 76–82 (1970).Google Scholar
  176. Selkon, J. B.: “Atypical” mycobacteria: A review. Tubercle (Lond.) Suppl.50 70–78 (1969).Google Scholar
  177. Somner, A. R.: Drug resistant tuberculosis treated with ethambutol and rifampicin in North East England. Tubercle (Lond.)51 222 (1970).Google Scholar
  178. —— Brace, A.: Ethionamide, pyrazinamide, and cycloserine used successfully in the treatment of chronic pulmonary tuberculosis. Tubercle (Lond.)43 345–360 (1962).Google Scholar
  179. Stewart, S. M., Murdoch, J. McC., Crofton, J. W., Hay, D.: Pyrazinamide together with oxytetracycline in patients with tubercle bacilli resistant to streptomycin, PAS and isoniazid. Brit. J. Tuberc.51 158–167 (1957).Google Scholar
  180. Stradling, P., Poole, G. W.: Twice weekly streptomycin plus isoniazid for tuberculosis. Tubercle (Lond.)51 44–47 (1970).Google Scholar
  181. Strandgaard, E.: Pulmonary tuberculosis in elderly and aged patients. Scand. J. resp. Dis. Suppl.72 83 (1970).Google Scholar
  182. Symposium sur les thioamides — leur place actuelle dans la lutte contre la tuberculose. Symposium tenu à l'occasion de la XXe Conférence de l'Union Internationale contre la Tuberculose à New York, le 3 Septembre 1969 (Modérateur E. Jančík, Rédaction E. Jančík, J. K. Kraan). Paris: (sous presse, Paris).Google Scholar
  183. Tacquet, A., Devulder, B.: Ethambutol in the treatment of pulmonary tuberculosis. Rev. Tuberc. (Paris)32 729–748 (1968).Google Scholar
  184. -- -- Martin, J. C., Daniel, H. Mme, Le Bouffant, L.: Activité antimycobactérienne de la rifampicine. Rev. Tuberc. (Paris)33 bis, 61–80 (1969).Google Scholar
  185. -- Savinel, E., Devulder, B., Duthot, A.: La rifampicine dans le traitement de la tuberculose pulmonaire (note préliminaire). Rev. Tuberc. (Paris)33 bis, 135–146 (1969).Google Scholar
  186. Tala, A.: Treatment of pulmonary diseases of elderly patients in hospital. Scand. J. resp. Dis. Suppl.74 8 (1970).Google Scholar
  187. Tani, P.: Medical and social aspects of chronic pulmonary tuberculosis in Finland. Scand. J. resp. Dis. Suppl.72 93–105 (1970).Google Scholar
  188. Toušek, J.: First experience with rifampicin in retreatment of resistant cases. Acta tuberc. pneumol. belg.60 478–481 (1969).PubMedGoogle Scholar
  189. —— Zelenka, M., Jančík, E.: Therapeutic possibilities in patients with pulmonary tuberculosis excreting tubercle bacilli resistant to INH, SM and PAS. Rozhl. Tuberk.29 398–413 (1969).Google Scholar
  190. —— Zítková, L., Čelíkovská, M., Štastná, J.: Prothionamide in clinical application. Stud. pneumol. phtiseol. csl.30 13–21 (1970).Google Scholar
  191. Trnka, L.: Mechanism of rifampicin action on mycobacterial cells. Considerations to the potentiation problem of antimycobacterial treatment. Acta tuberc. pneumol. belg.60 356–365 (1969).PubMedGoogle Scholar
  192. Tuberculosis Chemotherapy Centre, Madras: A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Bull. W. H. O.21 51–144 (1959).Google Scholar
  193. Tuberculosis Chemotherapy Centre, Madras: A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Tubercle (Lond.)40 468–478 (1959).Google Scholar
  194. —— Bull. W. H. O., Lancet,1959 II 1; 23, 535–585 (1960);31, 247 (1964);34, 483 (1966).Google Scholar
  195. Tuberculosis Society of Scotland: Prednison in the treatment of tuberculosis controlled trial. Brit. med. J.2 1131 (1957).Google Scholar
  196. Tucker, W. B.: Re-treatment of advanced pulmonary tuberculosis with viomycin. Amer. Rev. Tuberc.70 812–840 (1954).Google Scholar
  197. —— The evolution of the cooperative studies in the chemotherapy of tuberculosis of the Veterans Administration and Armed Forces of the U.S.A. Tuberc. Res.10 1–68 (1960).Google Scholar
  198. —— Matthews, J. H.: Pyrazinamide used with INH in the treatment of pulmonary tuberculosis. Bull. Un. int. Tuberc.29 549–555 (1959).Google Scholar
  199. United States Public Health Service — Tuberculosis Study Group: Preliminary observations from a controlled trial of prednisone in the treatment of tuberculosis. Amer. Rev. resp. Dis.81 598–600 (1960).Google Scholar
  200. United States Public Health Service Tuberculosis Therapy Trial: Ethambutol in re-treatment of pulmonary tuberculosis. Amer. Rev. resp. Dis.98 825–836 (1968).Google Scholar
  201. Vall-Spinosa, A., Lester, W., et al.: In: Rothstein, E.: The twenty ninth Veterans Administration — Armed Forces Pulmonary Diseases Research Conference. Amer. Rev. resp. Dis.101 783–801 (1970).Google Scholar
  202. Velu, S., Sambamoorthy, S.: A Note on the Relapse rate over a 4-year period in patients with quiescent pulmonary tuberculosis following treatment with reserve regimens. Tubercle (Lond.)19 410–412 (1968).Google Scholar
  203. Véran, P., Moigneteau, C., Trichereau, R., Rist, N.: Le 1314 Th ou thioamide de l'acide alpha-éthyl-isonicotinique dans le traitement de la tuberculose cavitaire. Rev. Tuberc. (Paris)23 533–569 (1959).Google Scholar
  204. Verbist, L.: Rifampicin blood levels in man. Acta tuberc. pneumol. belg.60 288–298 (1969).PubMedGoogle Scholar
  205. —— Experimental study of the activity of Rifampicin in vitro and in vivo. Tubercle (Lond.)50 327–328 (1969).Google Scholar
  206. —— Gyselen, A.: Antituberculous activity of Rifampicin in vitro and in vivo and the concentrations atteined in human blood. Amer. Rev. resp. Dis.68 923–932 (1968).Google Scholar
  207. Virchow, Chr., Flemming, J.: Combined treatment with rifampicin-ethambutol-capreomycin in chronic open pulmonary tuberculosis. Acta tuberc. pneumol. belg.60 448–470 (1969).Google Scholar
  208. W. A. T. L.: Kooperative kontrollierte Prüfung von Thiocarlid (DATC), PAS und Bettruhe in kurzfristiger Monotherapie bei kavernöser vorbehandelter Lungentuberkulose. Beitr. Klin. Tuberk.139 115–139 (1969).Google Scholar
  209. Weill, G., Varin, E., Stoeckel, Ch.: La rifampicine dans le traitement de la tuberculose pulmonaire. Rev. Tuberc. (Paris)33 283–290 (1969).Google Scholar
  210. Yeager, R. L., Munroe, W. C. C., Dessau, F. I.: Pyrazinamide (Aldinamide) in the treatment of pulmonary tuberculosis. Amer. Rev. Tuberc.65 523–534 (1952).Google Scholar
  211. Zaki, M. H., Edelstein, S., Josephson, R. A., Weisberg, S. R.: Regularity of drug administration among hospitalized and ambulatory tuberculous patients. Amer. Rev. resp. Dis.97 136–139 (1968).Google Scholar
  212. Zelenka, M., Jančík, E.: Viomycinsulfat und Viothenat — toxische und Nebenerscheinungen bei Behandlung von chronischen Tuberkulosefällen. Tuberk.-Arzt16 500–505 (1962).Google Scholar
  213. Zierski, M.: Die Behandlung der Lungentuberkulose bei resistenten Tuberkelbakterien. Beitr. Klin. Tuberk.125 15–21 (1962).Google Scholar
  214. —— The treatment of drug resistant chronic pulmonary tuberculosis with new tuberculostatics. Bull. Un. int. Tuberc.41 194–200 (1968).Google Scholar
  215. —— Zachara, A.: Late results in re-treatment of patients with pulmonary tuberculosis. Tubercle (Lond.)51 172–177 (1970).Google Scholar
  216. —— —— Woźniak, S.: Results of treatment with triple-drug regimes of reserve drugs in cavitary pulmonary tuberculosis. A study under the auspices of the International Union against Tuberculosis. Gruźlica36 809–818 (1968) (zit. Amer. Rev. resp. Dis.99, 638–639, 1969).Google Scholar

Copyright information

© Springer-Verlag 1971

Authors and Affiliations

  • E. Jancik
    • 1
  1. 1.GroningenNiederlande

Personalised recommendations